Home Acta Virologica 2010 Acta Virologica Vol.54, No.2, p.131-136, 2010

Journal info

Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Impact Factor = 1.82

Aims and Scope
Abstracted and Indexed

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.54, No.2, p.131-136, 2010

Title: HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model
Author: M. Mahdavi, M. Ebtekar, K. Azadmanesh, H. R. Khorramkhorshid, F. Rahbarizadeh, M. H. Yazdi, R. Zabihollahi, M. Abolhassani, Z. M. Hassan

Abstract: Many Human immunodeficiency virus (HIV) candidate vaccines have been tested in clinical trials, but none was sufficiently effective in the prevention of HIV infection. A HIV vaccine should induce humoral as well as cell-mediated response, the latter including the cytotoxic CD8+ T lymphocyte (CTL) response. In this study, we immunized BALB/c mice with a purified fusion peptide Gag p24-Nef and evaluated immune responses. As for the cellular responses, the adjuvanted fusion peptide induced lymphocyte proliferation, CTL response, and cytokines IFN-γ and IL-4 in the Th1 pattern. Humoral immune response to the adjuvanted fusion peptide included an increase in IgG antibodies of more IgG2a than IgG1 subtype. These results indicate that the employed HIV-1 peptide construct can elicit both cellular and humoral immune responses in mice. Further studies aimed at memory T cells and other aspects of immune responses are needed before a comprehensive assessment of this candidate vaccine could be provided.

Keywords: epitopes; fusion peptide; HIV-1 p24-Nef; immune response
Year: 2010, Volume: 54, Issue: 2 Page From: 131, Page To: 136
Price: 14.40 €

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.